Test Price
2,800 AED✅ Home Collection Available
CHRNB1 Gene Congenital Myasthenic Syndrome (CMS) Genetic Test in Dubai
Executive Summary & Core Metrics
The CHRNB1 gene NGS test provides a definitive molecular analysis of the nicotinic cholinergic receptor beta-1 subunit, targeting pathogenic variants responsible for congenital myasthenic syndrome (CMS). This highly sensitive diagnostic resource is critical for confirming suspected CMS in patients presenting with fatigable weakness, ptosis, or bulbar symptoms. The test facilitates precision treatment planning, including the appropriate use of acetylcholinesterase inhibitors, and provides essential data for accurate genetic counselling. Our laboratory adheres to DHA regulatory standards and UAE data privacy frameworks, ensuring full clinical validity and patient confidentiality.
99.9% Sensitivity
ISO-accredited NGS processing
Cold-Chain Home Collection
VIP phlebotomy 8 AM – 11 PM
Post-Test Clinical Guidance
Telephonic result interpretation
Insurance Billing
WhatsApp verification +971 54 548 8731
Test Overview & Methodology
This molecular diagnostic test utilizes advanced Next-Generation Sequencing (NGS) to perform a comprehensive analysis of the CHRNB1 gene, covering all coding exons and highly conserved splice-site regions. It is specifically designed for the detection of single-nucleotide variants (SNVs) and small insertions or deletions (indels) associated with congenital myasthenic syndrome. The high sensitivity and specificity of the NGS platform provide a robust alternative to traditional Sanger sequencing, offering deeper coverage and improved detection of mosaic variants. Results are correlated with clinical phenotype and family history to ensure accurate diagnostic interpretation and to guide therapeutic strategies.
| Feature | Our CHRNB1 NGS Test | Closest Alternative (Single-Gene Sanger) |
|---|---|---|
| Precision | Full gene analysis, all exons & splice sites | Selected hotspots only |
| Method | NGS (Next-Generation Sequencing) | Sanger sequencing |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Clinical Validation | 99.9% diagnostic sensitivity, ISO 9001:2015 | May not be ISO accredited |
| Pre-Test Support | Mandatory genetic counselling included | Often not provided |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
This single-gene sequencing test provides a highly specific molecular diagnosis for congenital myasthenic syndrome when the clinical presentation strongly points to CHRNB1 involvement. However, it is critical to correlate the genetic result with electrophysiological studies, such as repetitive nerve stimulation and single-fiber EMG, as well as the patient’s response to pyridostigmine. A negative result does not exclude CMS, as mutations in other genes (e.g., CHRNE, RAPSN, DOK7) can cause overlapping phenotypes. Comprehensive pre-test counselling and a detailed three-generation family pedigree are essential to interpret the result correctly and assess recurrence risks.
Safety Alerts & Exclusion Criteria
- Do not discontinue prescribed medication without consulting your doctor. This test does not replace acute clinical management for myasthenic crises.
- Exclusion criteria: Patients with active respiratory crisis or severe bulbar weakness should not postpone emergency care for sample collection; hospital admission may be required first.
- ER Red Flags: If you experience sudden worsening of muscle weakness, difficulty breathing, or impaired swallowing after sample collection, seek emergency medical attention immediately.
- Neonates and minors must have sample collection performed in the presence of a legal guardian, in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What does the CHRNB1 NGS test detect and how long does it take?
This advanced genetic test sequences the entire CHRNB1 gene to pinpoint mutations causing congenital myasthenic syndrome, with results typically available within 3 to 4 weeks. The test uses high-throughput next-generation sequencing (NGS) to analyse all coding exons and flanking intronic regions, ensuring high diagnostic sensitivity. Your clinical report will detail any identified mutation, its zygosity, and its association with disease, prepared by our DHA-licensed molecular geneticists.
2. Is a genetic counselling session mandatory before the test?
Yes, a pre-test genetic counselling session is mandatory to draw a detailed pedigree and obtain informed consent, aligning with DHA and UAE regulatory standards. Our certified genetic counsellors will explain the test’s scope, potential outcomes, and implications for family members. This session can be conducted online or in-clinic, and it ensures you fully understand the benefits and limitations of the result.
3. How is my DNA sample handled and what about privacy?
Your sample is collected by a trained phlebotomist using an ISO-certified cold-chain process and stored under strict UAE Personal Data Protection Law (PDPL) compliance. The DNA is analysed exclusively for the CHRNB1 gene as consented; no secondary use or sharing occurs without your explicit permission. All electronic records are encrypted, and only authorised medical professionals access the final report, which is delivered via a secure portal.
UAE Regulatory & Data Privacy Adherence
Data Protection and Health Information Governance
DNA Labs UAE strictly complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. These frameworks mandate rigorous data encryption, patient consent protocols, and strict limitations on the processing of genetic data. All genetic test results are stored in secure, access-controlled databases, and are only disclosed to the ordering physician or the patient upon verified request. Our laboratory infrastructure is audited annually to ensure sustained compliance with these national data privacy and health information governance standards.
Clinical & Logistical Metadata
| Test Name | CHRNB1 Gene Congenital Myasthenic Syndrome (CMS) Sequencing |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available Daily 8 AM – 11 PM) |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | G70.0 |
| LOINC Code | 101399-0 |
| DHA Facility License & Laboratory Address | DHA License Number 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians